Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE vs DAYPRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Brompheniramine is a first-generation antihistamine that competitively inhibits histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and nasal decongestion. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist that suppresses the cough reflex in the medulla oblongata.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and thereby alleviating pain and inflammation.
Symptomatic relief of upper respiratory symptoms associated with allergic rhinitis, common cold, or sinusitis including nasal congestion, rhinorrhea, sneezing, and cough.
Osteoarthritis,Rheumatoid arthritis
Adults and children ≥12 years: 1 tablet (brompheniramine maleate 4 mg, pseudoephedrine HCl 60 mg, dextromethorphan HBr 15 mg) orally every 4 hours, not to exceed 4 tablets in 24 hours, or 2 tablets (extended-release) every 12 hours, not to exceed 4 tablets in 24 hours.
600 mg orally once daily; max 1200 mg/day
Brompheniramine: 12-34 hours (mean ~24 h), prolonged in hepatic impairment. Pseudoephedrine: 5-8 hours (p H-dependent urinary excretion; alkaline urine prolongs half-life). Dextromethorphan: 3-4 hours (extensive metabolizers) or 18-24 hours (poor metabolizers of CYP2D6).
Approximately 40-70 hours (mean ~50 h), allowing once-daily dosing; steady-state reached in 4-6 days.
Brompheniramine: extensively metabolized via hepatic CYP450 (CYP2D6, CYP3A4) to desmethylbrompheniramine and other metabolites. Pseudoephedrine: partially metabolized via N-demethylation (CYP450) to norgseudoephedrine; 43-96% excreted unchanged. Dextromethorphan: primarily metabolized via CYP2D6 to dextrorphan (active), also via CYP3A4/5 to 3-methoxymorphinan.
Primarily hepatic via CYP2C9; undergoes glucuronidation.
Brompheniramine: Renal (approx. 80% as metabolites, <1% unchanged). Pseudoephedrine: Renal (70-90% unchanged, rest as metabolites). Dextromethorphan: Renal (primarily as metabolites, <1% unchanged). Biliary/fecal: Minor for all three.
Renal (approx. 70-80% as unchanged drug and glucuronide conjugate; biliary/fecal excretion accounts for the remainder).
Brompheniramine: 60-80% (primarily albumin, alpha-1-acid glycoprotein). Pseudoephedrine: <10% (negligible). Dextromethorphan: 50-60% (possibly to albumin).
>99% bound primarily to albumin.
Brompheniramine: 7-10 L/kg (large, due to extensive tissue distribution). Pseudoephedrine: 2.5-3.5 L/kg (moderate, distributes into body water). Dextromethorphan: 3-5 L/kg (moderate, distributed to tissues including brain).
0.15-0.2 L/kg; indicates limited extravascular distribution mainly in plasma and extracellular fluid.
Brompheniramine: ~70% (oral). Pseudoephedrine: 90-100% (oral). Dextromethorphan: ~10-30% (oral, due to extensive first-pass metabolism; in poor metabolizers, bioavailability higher).
Oral: approximately 80-90%.
GFR ≥30 m L/min: No adjustment. GFR 10-29 m L/min: Administer every 6 hours; monitor for CNS effects. GFR <10 m L/min: Avoid use (risk of toxicity from pseudoephedrine and dextromethorphan accumulation).
Cr Cl 30-59 m L/min: 600 mg once daily; Cr Cl <30 m L/min: 400 mg once daily; hemodialysis: 400 mg once daily after dialysis
Child-Pugh A: No adjustment. Child-Pugh B: Reduce frequency (e.g., every 6 hours) and monitor for CNS depression. Child-Pugh C: Avoid use (dextromethorphan metabolism reduced; brompheniramine may accumulate).
Child-Pugh Class A: no adjustment; Class B: 400 mg once daily; Class C: avoid use
Children 6-11 years: 1/2 tablet (brompheniramine maleate 2 mg, pseudoephedrine HCl 30 mg, dextromethorphan HBr 7.5 mg) orally every 4 hours, not to exceed 4 doses in 24 hours. Children 2-5 years: Not recommended (safety and efficacy not established). Children <2 years: Contraindicated (risk of respiratory depression).
Not approved for pediatric use
Elderly >65 years: Initiate at lowest effective dose (e.g., 1/2 tablet) every 6-8 hours due to increased anticholinergic effects, hypotension, and CNS excitation. Maximum: 2 tablets in 24 hours. Monitor for confusion, urinary retention, and elevated blood pressure.
Initiate at 400 mg once daily; max 600 mg once daily; monitor renal function
None.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. DAYPRO is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
Cardiovascular effects: hypertension, palpitations, tachycardia, arrhythmias, especially in patients with pre-existing heart disease or hyperthyroidism.,CNS depression: avoid concurrent use with alcohol or other sedatives; may impair mental/physical abilities.,Serotonin syndrome: risk with concomitant serotonergic drugs including MAOIs, SSRIs, SNRIs, triptans, linezolid, methylene blue.,QT prolongation: caution with drugs that prolong QT interval or predisposing conditions (e.g., electrolyte abnormalities, bradycardia).,Anticholinergic effects: caution in patients with glaucoma, prostatic hypertrophy, urinary retention, or asthma.,Inhibition of CYP2D6: dextromethorphan may increase levels of CYP2D6 substrates (e.g., TCAs, antipsychotics).
Cardiovascular risk, gastrointestinal bleeding and ulceration, renal toxicity, hypertension, anaphylactoid reactions, serious skin reactions, hematologic toxicity (anemia), hepatic effects, asthma exacerbation, fluid retention, and use in pregnancy (avoid in late pregnancy).
Hypersensitivity to any component,Concurrent use or within 14 days of MAO inhibitors (hypertensive crisis),Severe hypertension or coronary artery disease,Narrow-angle glaucoma,Urinary retention,During or immediately after treatment with serotonergic drugs (risk of serotonin syndrome)
Aspirin allergy, history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs, perioperative pain in the setting of CABG surgery, advanced renal disease, and pregnancy (third trimester).
Avoid alcohol, which may potentiate CNS depression. Limit caffeine intake (coffee, tea, cola) as pseudoephedrine may increase stimulant effects. High-tyramine foods (e.g., aged cheese, cured meats, fermented products) may cause hypertensive crisis if combined with MAOIs, but this combination is contraindicated. No other significant food interactions.
No significant food interactions. However, taking with food or antacids can reduce GI irritation. Avoid alcohol to minimize risk of gastric mucosal injury.
Brompheniramine: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Pseudoephedrine: Case-control studies suggest small increased risk of gastroschisis and hemifacial microsomia with first-trimester use; vasoconstriction may reduce uteroplacental blood flow in third trimester. Dextromethorphan: No human teratogenicity data; animal studies show no fetal harm at therapeutic doses. Overall, combination is not recommended in first trimester; avoid in third trimester due to pseudoephedrine effects.
Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with teratogenic potential. First trimester: Avoid; associated with increased risk of miscarriage and cardiac defects. Second trimester: Use only if clearly needed; possible oligohydramnios and fetal renal impairment. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal pulmonary hypertension.
Brompheniramine: excreted in breast milk in small amounts; may cause infant irritability or drowsiness. Pseudoephedrine: concentrated in breast milk (M/P ratio ~3.0); may reduce milk production. Dextromethorphan: likely excreted in breast milk but no data on infant levels. Avoid during breastfeeding due to potential infant CNS effects and reduced milk supply.
Oxaprozin is excreted into breast milk in low concentrations (M/P ratio approximately 0.1-0.3). Due to potential adverse effects on infant renal function and platelet function, caution is advised. Avoid long-term use; short-term use with infant monitoring recommended.
No specific dose adjustments studied for combination in pregnancy. Due to increased plasma volume and clearance, standard adult doses may be less effective; however, avoid use in pregnancy due to risks. No PK studies available.
No specific dose adjustments established; however, pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) may require dose titration based on clinical response. Use lowest effective dose for shortest duration. Avoid in third trimester.
Do not use in children under 6 years due to risk of respiratory depression from dextromethorphan. Avoid in patients with hypertension or coronary artery disease due to pseudoephedrine. Brompheniramine has pronounced anticholinergic effects; use cautiously in elderly or those with glaucoma, urinary retention, or BPH. For severe cough, dextromethorphan efficacy is limited; consider if nonproductive cough is disruptive. Maximum duration of treatment is 7 days; prolonged use may lead to rebound congestion and dependence.
Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with a long half-life (~50-60 hours) allowing once-daily dosing. Use with caution in elderly or renal impairment due to reduced clearance. Monitor renal function, hepatic enzymes, and signs of GI bleeding. Avoid use with other NSAIDs or aspirin. May increase lithium, methotrexate, and warfarin levels.
Do not take more than 6 doses in 24 hours. Do not exceed 7 days of use without consulting a doctor.,Avoid alcohol and other CNS depressants (e.g., sedatives, tranquilizers) as they may increase drowsiness.,Do not use if you have taken a monoamine oxidase inhibitor (MAOI) within the last 14 days.,Stop use and ask a doctor if symptoms do not improve within 7 days, are accompanied by fever, or if cough persists with headache, rash, or persistent headache.,Take with a full glass of water. May cause drowsiness; avoid driving or operating heavy machinery until you know how this medication affects you.,For the decongestant effect, take the last dose of the day several hours before bedtime to minimize insomnia.,Shake suspension well before use. Use only the dosing device provided.
Take with food or milk to reduce stomach upset.,Swallow tablets whole; do not crush or chew.,Avoid alcohol while taking this medication.,Report signs of bleeding (black/tarry stools, unusual bruising), weight gain, or edema.,Do not take with other NSAIDs or over-the-counter pain relievers without consulting your doctor.
"Brompheniramine, a first-generation antihistamine, may inhibit the hepatic metabolism of sulfamethoxazole, a sulfonamide antibiotic, via competitive inhibition of cytochrome P450 enzymes, particularly CYP2C9. This results in elevated plasma concentrations of sulfamethoxazole, potentially increasing the risk of dose-dependent adverse effects such as hypersensitivity reactions, crystalluria, and hematologic toxicity (e.g., agranulocytosis). Clinically, patients may present with prolonged or intensified drug effects, including increased bone marrow suppression and renal impairment, especially in those with pre-existing hepatic or renal dysfunction."
"Dextropropoxyphene, an opioid analgesic, and brompheniramine, a first-generation antihistamine with anticholinergic properties, can synergistically depress the central nervous system (CNS) and respiratory centers. This interaction increases the risk of profound sedation, respiratory depression, coma, and death, particularly in elderly patients or those with pre-existing respiratory or hepatic impairment. Concurrent use also amplifies anticholinergic adverse effects such as urinary retention, constipation, and cognitive dysfunction."
"Brompheniramine, a first-generation antihistamine with significant central nervous system (CNS) depressant properties, can potentiate the CNS depressant effects of brimonidine, an alpha-2 adrenergic agonist used for ocular hypertension and glaucoma. This interaction leads to additive sedation, drowsiness, and dizziness, which may impair cognitive and motor function, increasing the risk of falls and accidents. Severe cases could result in excessive CNS depression, including somnolence and respiratory depression, particularly in elderly patients or those with compromised hepatic function."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE vs DAYPRO, answered by our medical review team.
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE is a Sympathomimetic that works by Brompheniramine is a first-generation antihistamine that competitively inhibits histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and nasal decongestion. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist that suppresses the cough reflex in the medulla oblongata.. DAYPRO is a Nonsteroidal Anti-Inflammatory Drug (NSAID) that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and thereby alleviating pain and inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE and DAYPRO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE is: Adults and children ≥12 years: 1 tablet (brompheniramine maleate 4 mg, pseudoephedrine HCl 60 mg, dextromethorphan HBr 15 mg) orally every 4 hours, not to exceed 4 tablets in 24 hours, or 2 tablets (extended-release) every 12 hours, not to exceed 4 tablets in 24 hours.. The standard adult dose of DAYPRO is: 600 mg orally once daily; max 1200 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE and DAYPRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE is classified as Category A/B. Brompheniramine: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Pseudoephedrine: Case-control studies suggest small increased risk of gastr. DAYPRO is classified as Category C. Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with teratogenic potential. First trimester: Avoid; associated with increased risk of miscarriage and cardiac de. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.